Cyteph

Cyteph is an Australian clinical-stage biotechnology company developing allogeneic T cell and CAR T cell therapies, harnessing the power of the immune system to target and destroy solid tumours. Our innovative strategy uses the natural ability of cytomegalovirus (CMV)-specific T cells to recognise and attack cancer cells, making them an advantageous choice for immunotherapy.

The unique properties of these viral T cells are also leveraged in our proprietary 'Cyt-ATTAC' (Cytomegalovirus-Allogeneic Tumour TArgeting Car t) CAR delivery platform to enhance the safety, efficacy and persistence of CAR T cell therapy, with the potential to develop multiple CAR T products with dual-targeting capabilities.

Our approach aims to overcome the current challenges in treating solid tumours with immunotherapy and to develop novel treatments for patients who currently have limited or no options available.

300 Herston Road, Brisbane, Queensland 4006, AU